GC Wealth Management RIA LLC Sells 1,741 Shares of Stryker Co. (NYSE:SYK)

GC Wealth Management RIA LLC trimmed its position in shares of Stryker Co. (NYSE:SYK - Free Report) by 67.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 850 shares of the medical technology company's stock after selling 1,741 shares during the quarter. GC Wealth Management RIA LLC's holdings in Stryker were worth $306,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently modified their holdings of SYK. Miller Financial Services LLC purchased a new stake in shares of Stryker in the 4th quarter worth $587,000. King Luther Capital Management Corp increased its stake in shares of Stryker by 0.5% in the 4th quarter. King Luther Capital Management Corp now owns 395,968 shares of the medical technology company's stock worth $142,568,000 after purchasing an additional 2,142 shares in the last quarter. Citizens Financial Group Inc. RI increased its stake in shares of Stryker by 0.8% in the 4th quarter. Citizens Financial Group Inc. RI now owns 56,103 shares of the medical technology company's stock worth $20,200,000 after purchasing an additional 430 shares in the last quarter. Davis R M Inc. increased its stake in shares of Stryker by 7.3% in the 4th quarter. Davis R M Inc. now owns 133,017 shares of the medical technology company's stock worth $47,893,000 after purchasing an additional 9,057 shares in the last quarter. Finally, Independent Advisor Alliance increased its stake in shares of Stryker by 19.4% in the 4th quarter. Independent Advisor Alliance now owns 8,149 shares of the medical technology company's stock worth $2,934,000 after purchasing an additional 1,325 shares in the last quarter. 77.09% of the stock is owned by institutional investors.

Analysts Set New Price Targets

SYK has been the subject of several analyst reports. JPMorgan Chase & Co. upped their price objective on Stryker from $420.00 to $445.00 and gave the stock an "overweight" rating in a research note on Wednesday, January 29th. StockNews.com lowered Stryker from a "buy" rating to a "hold" rating in a research note on Thursday, March 6th. Royal Bank of Canada increased their price target on Stryker from $425.00 to $435.00 and gave the stock an "outperform" rating in a research note on Wednesday, January 29th. Morgan Stanley upgraded Stryker from an "equal weight" rating to an "overweight" rating and increased their price target for the stock from $370.00 to $445.00 in a research note on Monday, December 2nd. Finally, Wells Fargo & Company increased their price target on Stryker from $427.00 to $435.00 and gave the stock an "overweight" rating in a research note on Wednesday, January 29th. Five equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $421.90.

Remove Ads

Insiders Place Their Bets

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of the firm's stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the sale, the director now owns 3,642,075 shares of the company's stock, valued at $1,428,567,498. This trade represents a 5.24 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Allan C. Golston sold 2,458 shares of the firm's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the sale, the director now directly owns 14,895 shares of the company's stock, valued at approximately $5,705,827.65. The trade was a 14.16 % decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is owned by insiders.

Stryker Stock Down 1.3 %

Shares of NYSE:SYK opened at $365.35 on Wednesday. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. Stryker Co. has a 12 month low of $314.93 and a 12 month high of $406.19. The company has a 50-day moving average price of $382.70 and a 200 day moving average price of $373.40. The company has a market cap of $139.41 billion, a price-to-earnings ratio of 47.08, a PEG ratio of 2.93 and a beta of 0.95.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating analysts' consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period in the prior year, the business posted $3.46 earnings per share. As a group, equities research analysts predict that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 0.92%. The ex-dividend date is Monday, March 31st. Stryker's payout ratio is currently 43.30%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.